Cancer
Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule
Published in Drug Law Weekly, June 23rd, 2009
"Prospect Therapeutics' lead product candidate, GCS-100, is a carbohydrate molecule which inhibits the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers. Prospect reported that GCS-100 could induce apoptosis of cancer cells and that clinical trial results indicated that reduction in leukemic cell number could be obtained without severe side effects.
"In addition to its direct effect on tumor cells, GCS-100 could have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-06-23)
More Articles from Drug Law Weekly
- A.P. Pharma, Inc.
A.P. Pharma Receives Extension for Nasdaq Listing Compliance - American Dietetic Association
Statement by American Dietetic Association Supporting Scientifically Valid, Informative Restaurant Labeling as Part of Health Reform - Antares Pharma, Inc.
Antares Pharma, Inc. to Present at Noble Financial’s Fifth Annual Equity Conference - Bioengineering
CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement - Biologics
Hospira Launches Biologics "Clock" and Web Resource to Raise Awareness of Potential Biogenerics' Imapct - Brinker International, Inc.
Brinker International Announces Support of Senate's Agreement on Uniform Nutrition Disclosure - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
